PinnyPeptide

Colivelin vs PE22-28

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Colivelin

Cognitive

Hybrid Humanin / ADNF peptide — high-potency neuroprotective agent for Alzheimer's research.

Peptide B

PE22-28

Cognitive

Fast-acting antidepressant peptide acting via TREK-1 channel inhibition.

Typical vial

10 mg

Typical dose

100-500 mcg

Half-life

~hours (longer than parent Humanin)

FDA status

Not FDA approved.

Typical vial

5 mg

Typical dose

50-200 mcg

Half-life

Hours; precise value species-dependent

FDA status

Not FDA approved.

Colivelin effects

  • Femtomolar-range neuroprotection against amyloid-β toxicity
  • Activates STAT3 pro-survival signaling
  • Engages ADNF neurotrophic signaling
  • Attenuates cognitive deficits in Alzheimer's mouse models
  • Activity in ALS and stroke animal models

PE22-28 effects

  • Selective TREK-1 potassium channel inhibition
  • Fast-onset antidepressant-like effects in rodent models
  • Increased serotonergic neuron firing in dorsal raphe
  • Enhanced BDNF / TrkB signaling downstream
  • Anti-anxiety effects in some assays

Colivelin side effects

  • Essentially uncharacterized in humans
  • Long-term safety data unavailable
  • Theoretical: off-target STAT3 activation effects
  • Injection-site reactions

PE22-28 side effects

  • Essentially uncharacterized in humans
  • Theoretical: TREK-1 inhibition off-target in heart, immune cells
  • Subjective reports of mood activation, occasional anxiety
  • Injection-site reactions
  • Sleep disturbance with late-day dosing

Colivelin dosing ranges

Neuroprotection research (intranasal)

100-500 mcg · Once daily · Per research protocol

Subcutaneous research

100-500 mcg · Once daily · Per research protocol

PE22-28 dosing ranges

Antidepressant research (preclinical)

100-500 mcg/kg · Daily SubQ or IP · Per protocol

Self-experimentation (no clinical guidance)

50-200 mcg · Once or twice daily · 2-4 weeks per cycle

Full Colivelin guide → Full PE22-28 guide →

Colivelin vs PE22-28 — common questions

What is the difference between Colivelin and PE22-28?

Colivelin: Hybrid Humanin / ADNF peptide — high-potency neuroprotective agent for Alzheimer's research. Typical dose 100-500 mcg. PE22-28: Fast-acting antidepressant peptide acting via TREK-1 channel inhibition. Typical dose 50-200 mcg. Both fall under the Cognitive category.

Can you stack Colivelin and PE22-28?

Stacking Colivelin with PE22-28 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Colivelin or PE22-28?

Colivelin is typically dosed: Once daily for Neuroprotection research (intranasal); Once daily for Subcutaneous research. PE22-28 is typically dosed: Daily SubQ or IP for Antidepressant research (preclinical); Once or twice daily for Self-experimentation (no clinical guidance).

Are Colivelin and PE22-28 FDA approved?

Colivelin: Not FDA approved. PE22-28: Not FDA approved.

Related peptide comparisons

adamax vs colivelincolivelin vs dihexacolivelin vs dnsp-11colivelin vs p21colivelin vs pinealonadamax vs pe22-28

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free